Sunitinib 12.5, 25, 37.5 & 50 Cipla 12.5 mg, 25 mg, 37.5 mg & 50 mg Capsule
PDF Leaflet Revision Date: 22 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of GIST, MRCC, and pNET.
Dosage (summary)
GIST/MRCC: 50 mg daily for 4 weeks, then 2-week rest. pNET: 37.5 mg daily.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to sunitinib
- Pregnancy
- Lactation
Common side effects
- Fatigue
- Diarrhoea
- Nausea
- Hypertension
- Skin rash
Counselling Points
- Monitor blood pressure regularly
- Avoid pregnancy during treatment
- Report any skin reactions immediately
Serious warnings
- Severe cutaneous reactions
- Haemorrhage
- Gastrointestinal perforation
- Cardiovascular events
Important Disclaimer
The Sunitinib 12.5, 25, 37.5 & 50 Cipla 12.5 mg, 25 mg, 37.5 mg & 50 mg Capsule professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
